Macmillan Cancer Support responds to NHS England on introduction of cancer drugs

Responding to an announcement by NHS England that it will fast-track the introduction of new cancer drugs that target tumours according to their genetic make-up, Dany Bell, Specialist Adviser for Treatment and Recovery at Macmillan Cancer Support, says: 

“It’s exciting that new cancer drugs may be available on the NHS, if they are approved by the National Institute for Health and Care Excellence, to help people receive more effective and targeted treatment. 

“Of course, no new treatment can be safely administered without enough doctors and nurses with the right skills and resources to both deliver it and support patients through their treatment. We urgently need investment to support hardworking NHS staff to deliver the personalised care that the increasing number of people living with cancer need. The new Prime Minister must make investing in the NHS workforce an absolute priority for their government.”